




PHARMACEUTICAL 2019

BeiGene Ltd.
Rank 105 of 363





RealRate

PHARMACEUTICAL 2019

BeiGene Ltd.
Rank 105 of 363



The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 62% points. The greatest weakness of BeiGene Ltd. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 134% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	1,943,842
Cost of Goods Sold	28,705
Intangible Assets	7,281
Liabilities, Current	246,452
Liabilities, Non-Current	249,585
Other Assets	141,500
Other Compr. Net Income	2,007
Other Expenses	-14,902
Other Liabilities	0
Other Net Income	15,940
Other Revenues	198,220
Property and Equipment	157,061
Research and Development	679,005
Selling, General and Administrative Expense	195,385

Output Variable	Value in 1000 USD
Assets	2,249,684
Liabilities	496,037
Expenses	888,193
Revenues	198,220
Stockholders Equity	1,753,647
Net Income	-674,033
Comprehensive Net Income	-673,030
Economic Capital Ratio	171%